Kura Oncology (KURA) Retained Earnings (2010 - 2026)
Kura Oncology (KURA) posted quarterly Retained Earnings of -$1.2 billion for Q1 2026, down 30.91% year-over-year from -$1.8 billion in Q1 2025, and down 6.25% quarter-over-quarter from -$1.2 billion in Q4 2025.
Kura Oncology (KURA) Retained Earnings (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Retained Earnings for 17 consecutive years, with -$1.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 30.91% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 30.91% YoY), while the FY2025 annual figure was -$1.2 billion, down 153776.44% from the prior year.
- Retained Earnings eased to -$1.2 billion in Q1 2026 per KURA's latest filing, from -$1.2 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $1.1 million in Q3 2024 and bottomed at -$1.2 billion in Q1 2026.
- Historically, Retained Earnings has averaged -$475.9 million across 5 years, with a median of -$535.7 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 567486.59% — and 2025, when it surged 253.56%.
- Kura Oncology's Retained Earnings stood at -$568.8 million in 2022, then fell by 26.83% to -$721.4 million in 2023, then jumped by 100.11% to $764000.0 in 2024, then plunged by 153776.44% to -$1.2 billion in 2025, then dropped by 6.25% to -$1.2 billion in 2026.
- Business Quant data shows KURA's Retained Earnings at -$1.2 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | -1.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.32 Bn |
| Mar 31, 2026 | -1.25 Bn |
| Dec 31, 2025 | -1.17 Bn |
| Sep 30, 2025 | -1.09 Bn |
| Jun 30, 2025 | 711,000.00 |
| Mar 31, 2025 | -952.85 Mn |
| Dec 31, 2024 | 764,000.00 |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | -463,000.00 |
| Mar 31, 2024 | -816,000.00 |
| Dec 31, 2023 | -721.44 Mn |
| Sep 30, 2023 | -678.65 Mn |
| Jun 30, 2023 | -640.05 Mn |
| Mar 31, 2023 | -5.90 Mn |
| Dec 31, 2022 | -568.81 Mn |
| Sep 30, 2022 | -535.69 Mn |
| Jun 30, 2022 | -7.82 Mn |
| Mar 31, 2022 | -465.42 Mn |
| Dec 31, 2021 | -432.97 Mn |
| Sep 30, 2021 | -400.23 Mn |